Introduction: In 2019, a new coronavirus disease spread throughout the world from the city of Wuhan, China. COVID-19 is divided into four groups according to clinical symptoms and disease severity: mild, moderate, severe, and critical. Budgeted rates of CRP and albumin utilization will be used to estimate the incidence of COVID-19 cases. Based on this data, the aim of this study is to evaluate the diagnostic power of the C-reactive protein to albumin ratio in the early differentiation of severe hospitalized cases of COVID-19.
Materials and Methods: During hospitalization, cases will be classified as mild, moderate, severe, and critical according to the WHO interim guidance. The mild and moderate subgroups will be classified as non-severe (group 1), and the severe and critical subgroups will be classified as severe (group 2). Demographic data, morbidity, and mortality rates will be recorded.
Results: The exitus rates and length of hospital stay were significantly higher in group 2.
Conclusions: The C-reactive protein/albumin ratio has predictive value in severe COVID-19 patients who are candidates for ICU admission or endotracheal intubation. However, it is thought that supporting this data with a larger number of patients and multicenter studies would increase the value of the data.
